MaxWell Biosystems Launches Commercial Expansion: Strengthening Regional Presence in EMEA
Dr. Marie Obien
MaxWell Biosystems AG is advancing its global go-to-market strategy with the establishment of a dedicated EMEA regional team, expanding its presence and partnerships across Europe, the Middle East, and Africa. This move is part of the company’s global commercial evolution as demand continues to rise for its high-resolution electrophysiology platforms.
The newly formed EMEA regional team unites sales, business development, account management, and customer success roles to accelerate adoption, strengthen collaborations, and better serve the evolving needs of users in research and drug discovery across the region.
“Regional empowerment is a key step in scaling MaxWell Biosystems’ presence and performance across EMEA,” said Marie Obien, CCO of MaxWell Biosystems. “With a focused team in place, we are engaging more closely with our users, expanding our customer base, and executing with greater precision across key biopharma and academic markets in the region.”
EMEA is one of the regions established under this model, with other expansions ongoing in Asia-Pacific and the Americas. Leading the EMEA team is Giulio Zorzi, a seasoned commercial leader returning to MaxWell Biosystems with a strong track record of translating scientific potential into customer success.
The regionalization initiative reinforces MaxWell Biosystems’ commitment to scalable, customer-centric growth and broader scientific impact—advancing its mission to empower breakthroughs in neuroscience and drug discovery through next-generation high-content electrophysiology.
Contact
Dr. Marie Obien
Chief Commercial Officer
Phone +41 44 244 24 19
marie.obien@mxwbio.com
About MaxWell Biosystems
MaxWell Biosystems AG develops high-content electrophysiology platforms that accelerate drug discovery and advance the understanding of complex neuronal systems. Established in 2016 as a spin-off from ETH Zurich, the company is a leading expert in high-density microelectrode array (HD-MEA) technology, offering both proprietary hardware and software solutions. Its first product, MaxOne, enables detailed single-well analysis of cellular activity at network, cellular, and subcellular levels. The subsequent release of MaxTwo, a multi-well HD-MEA platform, significantly increases assay throughput with 6- and 24-well formats, addressing the needs of pharmaceutical companies, biotechnology firms, and contract research organizations. By equipping scientists with precise, scalable tools for in vitro functional analysis, MaxWell Biosystems empowers breakthroughs in neuroscience, disease modeling, and translational research.
Every cell has a story to tell.
Related
Resources
MaxOne
Versatility and functionality in one compact device
MaxTwo
Maximize your cell functional assays
MaxLab Live
All-in-one Software
Our Technology
Multi-/Micro-electrode Arrays
